Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

38%

3 of 8 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

5(62.5%)

Phase 3

3(37.5%)

8Total

Phase 1(5)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT01381796Phase 1Completed

Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults

Role: lead

NCT02684409Phase 1Completed

Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine

Role: lead

NCT00792103Phase 3Completed

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

Role: lead

NCT00806546Phase 3Completed

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

Role: lead

NCT00724815Phase 3Completed

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

Role: lead

NCT00723983Phase 1Completed

Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

Role: lead

NCT00546650Phase 1Completed

Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®

Role: lead

NCT00720018Phase 1Completed

Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers

Role: lead

All 8 trials loaded